Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Pulmovant has announced positive results from the PHocus study involving mosliciguat, a drug originally developed by Bayer as an inhaled hypertension medication. According to reports from Fierce Biotech, Roivant made a $14 million bet on this specific asset, which has now paid off following a phase 2 win. The drug is being targeted for the treatment of pulmonary hypertension associated with interstitial lung disease, referred to in coverage as PH-ILD. The recent data indicates that the medication hit its mid-stage study goals, marking a significant milestone in the drug's development cycle. Coverage from multiple outlets emphasizes the scale of the clinical success. TradingView reports that mosliciguat delivered what it describes as unprecedented pulmonary vascular resistance (PVR) reduction alongside functional gains in patients with PH-ILD.

Furthermore, the data indicated a strong safety profile for the treatment. This development was highlighted by STAT, which confirmed that the lung disease drug successfully hit its mid-stage study goals. The financial implications were also noted by Investor's Business Daily, which categorized the news as part of a 'blowout' and 'bull case' scenario that caused two biotech stocks to rise significantly. To understand why this matters, one must look at the history of the asset. The drug was an inhaled hypertension medication from Bayer before Roivant acquired the rights in a $14 million transaction. The focus has shifted toward PH-ILD, a complex condition where the pulmonary vascular resistance needs to be reduced to improve patient function.

The successful phase 2 PHocus study provides the first concrete evidence that this specific inhaled delivery method can achieve the necessary functional gains and PVR reduction required for regulatory progression in this patient population. Looking forward, the industry will monitor the transition of mosliciguat from these mid-stage goals into subsequent development phases. Market observers, including those following the 'bull case' reported by Investor's Business Daily, will likely watch for further data on the long-term safety and efficacy of the drug. As Pulmovant has officially announced the positive PHocus study results via GlobeNewswire, the next steps will involve leveraging these unprecedented reductions in PVR to move toward potential late-stage trials or regulatory filings.